Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Up 84.5% in December

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 187,800 shares, a growth of 84.5% from the November 30th total of 101,800 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily trading volume, of 6,130,000 shares, the short-interest ratio is presently 0.0 days.

Aptose Biosciences Stock Performance

Aptose Biosciences stock opened at $0.24 on Friday. The business has a fifty day moving average of $0.28 and a two-hundred day moving average of $0.45. The company has a market cap of $14.50 million, a P/E ratio of -0.08 and a beta of 1.06. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.68.

Analyst Upgrades and Downgrades

APTO has been the topic of several research reports. StockNews.com started coverage on Aptose Biosciences in a research note on Monday, December 23rd. They set a “hold” rating on the stock. HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a report on Tuesday, December 10th.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp boosted its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.